Molecular imaging will replace myocardial perfusion imaging

Journal of Nuclear Cardiology

Volumn 15, Issue 3, 2008, Pages 429-434

  Gropler, Robert J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUORODEOXYGLUCOSE F 18; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AORTA ATHEROSCLEROSIS; ATHEROSCLEROSIS; BIOLUMINESCENCE; CAROTID ARTERY DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY OBSTRUCTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; EMBRYONIC STEM CELL; GENE TECHNOLOGY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE PERFUSION; HUMAN; IMAGING SYSTEM; MOLECULAR IMAGING; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REPORTER GENE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL TRANSPLANTATION;

CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; HUMANS; IMAGE ENHANCEMENT; MOLECULAR PROBE TECHNIQUES;

EID: 44149113027     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nuclcard.2008.04.002     Document Type: Review

References (28)

1. The myocardial perfusion imaging market guide (U.S.) supplement to the U.S. imaging market guide (2007), Arlington Medical Resources, Malvern (PA)
2. Massoud T.F., and Gambhir S.S. Molecular imaging in living subjects: Seeing fundamental biological processes in a new light. Genes Dev 17 (2003) 545-580
3. Jaffer F.A., and Weissleder R. Molecular imaging in the clinical arena. JAMA 293 (2005) 855-862
4. Tempany C.M., and McNeil B.J. Advance in biomedical imaging. JAMA 285 (2001) 562-567
5. Hengerer A., Wunder A., Wagenaar D.J., Vija A.H., Shah M., Grimm J., et al. From genomics to clinical molecular imaging. IEEE Eng Med Biol Mag 93 (2005) 819-828
6. Wu J.C., Bengel F.M., and Gambhir S.S. Cardiovascular molecular imaging. Radiology 244 (2007) 337-355
7. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
8. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., and Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 (2006) 1549-1555
9. Hogan P., Dall T., Nikolov, and American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 26 (2003) 917-932
10. Jain K.K. Personalized medicine. Curr Opin Mol Ther 4 (2002) 548-558
11. Davies J.R., Rudd J.H., Weissberg P.L., and Narula J. Radionuclide imaging for the detection of inflammation in vulnerable plaques. J Am Coll Cardiol 47 Suppl (2006) C57-C68
12. Su H., Spinale F.G., Dobrucki L.W., Song J., Hua J., Sweterlitsch S., et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 112 (2005) 3157-3167
13. Cao F., Lin S., Xie X., Ray P., Patel M., Zhang X., et al. In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation 113 (2006) 1005-1014
14. Mayr M., Madhu B., and Xu Q. Proteomics and metabolomics combined in cardiovascular research. Trends Cardiovasc Med 17 (2007) 43-48
15. Griffin J.L., and Nicholls A.W. Metabolomics as a functional genomic tool for understanding lipid dysfunction in diabetes, obesity and related disorders. Pharmacogenomics 7 (2006) 1095-1107
16. Mayr M., Chung Y.L., Mayr U., Yin X., Ly L., Troy H., et al. Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism. Arterioscler Thromb Vasc Biol 2 (2005) 2135-2142
17. Brindle J.T., Antti H., Holmes E., Tranter G., Nicholson J.K., Bethell H.W., et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 8 (2002) 1439-1444
18. Rahmim A., Cheng J.C., Blinder S., Camborde M.L., and Sossi V. Statistical dynamic image reconstruction in state-of-the-art high-resolution PET. Phys Med Biol 50 (2005) 4887-4912
19. Liu C., Bhattacharjee G., Boisvert W., Dilley R., and Edgington T. In vivo interrogation of the molecular display of atherosclerotic lesion surfaces. Am J Pathol 163 (2003) 1859-1871
20. Iverson N., Plourde N., Chnari E., Nackman G.B., and Moghe P.V. Convergence of nanotechnology and cardiovascular medicine: progress and emerging prospects. BioDrugs 22 (2008) 1-10
21. Sun E.Y., Josephson L., and Weissleder R. "Clickable" nanoparticles for targeted imaging. Mol Imaging 5 (2006) 122-128
22. Gillies J.M., Prenant C., Chimon G.N., Smethurst G.J., Dekker B.A., and Zweit J. Microfluidic technology for PET radiochemistry. Appl Radiat Isot 64 (2006) 333-336
23. Nahrendorf M., Zhang H., Hembrador S., Panizzi P., Sosnovik D.E., Aikawa E., et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 117 (2008) 379-387
24. Hsueh W.A., and Law R.E. PPARγ and atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 1891-1895
25. Lautamäki R., Airaksinen K.E., Seppänen M., Toikka J., Luotolahti M., Ball E., et al. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: A 16-week randomized, double-blind, placebo-controlled study. Diabetes 54 (2005) 2787-2794
26. Kitamoto S., and Egashira K. Anti-monocyte chemoattractant protein-1 gene therapy for cardiovascular diseases. Expert Rev Cardiovasc Ther 1 (2003) 393-400
27. Tiwari R.L., Singh V., and Barthwal M.K. Macrophages: An elusive yet emerging therapeutic target of atherosclerosis. Med Res Rev 28 (2008) 483-544
28. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry. Providing regulatory submissions to CBER in electronic format-investigational new drug applications (INDs). www.fda.gov/cber/gdlns/eind.pdf